Two hundred twenty-eight members of the House of Representatives yesterday urged the Centers for Medicare & Medicaid Services to abandon its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program. “Given the important role that the 340B program plays in our communities, we strongly urge CMS to abandon this proposal and redirect its efforts toward actions to address the cost of drugs via other policies that would not harm our constituents,” the representatives wrote. CMS has proposed to pay for separately payable, non pass-through drugs purchased through the 340B program at the average sales price minus 22.5%, rather than the current rate of ASP plus 6%. Reps. David McKinley (R-WV), Mike Thompson (D-CA) and David Kustoff (R-TN) spearheaded the letter. “The AHA thanks Representatives McKinley, Thompson, and Kustoff for leading this bipartisan effort to protect patient care by urging CMS to rescind its misguided proposal to reduce Medicare Part B payments for 340B hospitals,” said AHA Executive Vice President Tom Nickels.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services May 21 announced it will immediately begin annual audits of all Medicare Advantage plans and work to clear a…
Headline
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…
Headline
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law…
Headline
The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models. “The 340B…
Headline
The AHA May 8 filed an amicus brief in the U.S. District Court for the District of Nebraska in defense of the state’s 340B contract pharmacy law prohibiting…